.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,037,525

« Back to Dashboard

Claims for Patent: 7,037,525

Title:Oxacarbazepine film-coated tablets
Abstract:The invention relates to formulations, e.g. film-coated tablets containing oxcarbazepine and to processes for the production of said formulations. The film-coated tablets have a tablet core comprising a therapeutically effective dose of oxacarbazepine being in a finely ground form having a mean particle size of from 4 to 12 .mu.m (median value), and a hydrophilic permeable outer coating.
Inventor(s): Schlutermann; Burkhard (Au, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:10/429,634
Patent Claims: 1. A method of treating seizures, which comprises administering a formulation of oxacarbazepine having improved bioavailability, wherein said oxacarbazepine consists essentially of oxacarbazepine having a maximum residue on a 40 .mu.m sieve of less than or equal to 5%.

2. The method according to claim 1 wherein said maximum residue on a 40 .mu.m sieve is less than or equal to 5%.

3. The method according to claim 1 wherein said formulation is substantially free from particles greater than or equal to 40 .mu.m in size.

4. The method according to claim 1 wherein the seizures results from the onset of epilepsy.

5. A method of treating seizures, comprising oral administration of a formulation of oxacarbazepine, wherein said formulation comprise a therapeutically effective dose of oxacarbazepine and wherein said oxacarbazepine has a median particle size of approximately 2 .mu.m to 12 .mu.m.

6. The method according to claim 5 wherein said oxacarbazepine has a median particle size of approximately 4 .mu.m to 10 .mu.m.

7. The method according to claim 5 wherein said oxacarbazepine has a median particle size of approximately 6 .mu.m to 8 .mu.m.

8. The method according to claim 5 wherein said oxacarbazepine has a maximum residue on a 40 .mu.m sieve of less than or equal to 5%.

9. The method according to claim 5 wherein said oxacarbazepine has a maximum residue on a 40 .mu.m sieve of less than or equal to 2%.

10. The method of claim 1, wherein said oxacarbazepine has a median particle sie of approximately 2 .mu.m to 12 .mu.m.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc